Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00305760 · ClinicalTrials.gov registry record · Phase 2

Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

A Phase 2 study of Pancreatic Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT00305760 is a Phase 2 study of Pancreatic Cancer that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 60 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00305760, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with cyclophosphamide and cetuximab may kill more tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works when given together with cyclophosphamide and cetuximab in treating patients with metastatic or locally advanced pancreatic cancer.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG Cyclophosphamide
  • DRUG Cetuximab
  • BIOLOGICAL Pancreatic tumor vaccine

Study Locations (1)

Maryland

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2005-12
Est. Completion 2009-03
Phase Phase 2

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

523 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00305760

The ClinicalTrials.gov registry entry for NCT00305760 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT00305760 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT00305760 about?

NCT00305760 is a clinical study titled "Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer". RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoc...

What is the current status of trial NCT00305760?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2005-12. Estimated completion is 2009-03.

What conditions does trial NCT00305760 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT00305760?

The interventions under investigation include: Cyclophosphamide (DRUG), Cetuximab (DRUG), Pancreatic tumor vaccine (BIOLOGICAL).

Who is sponsoring clinical trial NCT00305760?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00305760 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.